Off-the-shelf natural killer cell therapy company, targeting solid and hematological cancers Raises US$8M from US-based investor Acorn Bioventures and current shareholders, bringing total raised in last six months to US$14.6M Funding will enable expansion of R&D and manufacturing capabilities, and progression of its two lead programs towards the clinic: ONKT101 a dual-targeted NK cell therapy […]

Avectas announced that it has exclusively licenced from ONK Therapeutics (ONK) a Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy incorporating ONK’s proprietary Death Receptor (DR5) TRAIL variant for the treatment of B-cell malignancies.  Under the collaboration, ONK will be responsible for rapidly progressing the potential therapy to a Phase I clinical trial.  The […]